BMS: Broken patent office proceedings killing innovation
This article was originally published in Scrip
While Senator Charles Grassley (Republican-Iowa), chairman of the Senate Judiciary Committee, on 7 May said he was "comfortable with where we are on the language" of a bill aimed at again overhauling the US patent system, the lawmaker said he's also heard the pleas by some stakeholders, including the biopharmaceutical industry, to make tweaks to certain US Patent & Trademark Office (US PTO) proceedings, known as the post-grant (PGR) and inter partes (IPR) reviews.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.